GMA301 was selected as “National Mega-Innovative Program”

April 6, 2017, GMA301 was selected as the “National Mega-Innovative Program” for the 13th Five Year Plan.

GMA102/105 entered phase 2 clinical trial in Australia and New Zealand

June 1, 2017, GMA102/105 has started phase Ib/IIa clinical trial in Australia and New Zealand.

GMAX to Present at the International Diabetes Federation Congress 2017

October 5, 2017, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today...

First Patient Dose of GMA102 in the Phase II Clinical Trial for Treatm

December 7, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today ...

GMAX Initiates First-in-human Trial of GMA301 in Australia

December 16, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today ...